Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD 0200390 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 15 mg | EXPERIMENTAL | - |
| 25 mg | EXPERIMENTAL | - |
| 35 mg | EXPERIMENTAL | - |
| 5 mg | EXPERIMENTAL | - |
| 50 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 30 mg | EXPERIMENTAL | - |
| 60 mg | EXPERIMENTAL | - |
| 15 mg PD 0200390 | EXPERIMENTAL | - |
| 30 mg PD 0200390 | EXPERIMENTAL | - |
| 45 mg PD 0200390 | EXPERIMENTAL | - |
| 60 mg PD 0200390 | EXPERIMENTAL | - |
| Placebo PD 0200390 | EXPERIMENTAL | - |
| A425 | EXPERIMENTAL | A425 Treated |
| Name | Type | Description |
|---|---|---|
| PD 0200390 | DRUG | oral 15 mg daily dose, 3 capsules per dose during a six week treatment period. |
| Placebo | DRUG | oral placebo daily dose, 3 capsules per dose during a six week treatment period. |
Inclusion Criteria: * Awake unrestored or unrefreshed, associated with significant distress or impairment in social, occupational, or other important areas of functioning during the daytime, for at least 3 nights for the past 3 months prior to screening * Self-report wake after sleep onset \<45 min...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan, Astra-Zeneca |
| ResMed Inc. | RMD | 1 | N/A | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | - | Daridorexant, Non-orexin receptor antagonist medications for insomnia |
PD 0200390 is an investigational small molecule being developed for primary insomnia, insomnia, and nonrestorative sleep. It has been studied in Phase 2 clinical trials in adults with these sleep conditions.
PD 0200390 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The drug is a small molecule in the psychiatry therapeutic area.
PD 0200390 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. All completed trials for the drug are Phase 2 trials.
PD 0200390 has been studied in several completed trials. NCT00551148 was a dose-ranging polysomnography trial in primary insomnia with 92 participants. NCT00569972 was a randomized, double-blind, placebo-controlled outpatient trial in insomnia with 682 participants. NCT00655369 was a placebo-controlled trial in nonrestorative sleep with 306 participants.
PD 0200390 and PD 00200390 appear to refer to the same drug. A clinical trial listed as NCT00655369 uses the name PD 00200390 and studies the same condition of nonrestorative sleep in adults.